Q-Sera
Developer of blood serum collection tube designed to be created with coagulant properties of snake venom-derived proteins. The company's blood serum collection tube contain highly potent prothrombin activators found in snake venom which is manufactur.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
N/A | - | ||
| Total Funding | 000k | ||
Related Content
Q-Sera operates in the medical technology sector, specializing in the development and commercialization of advanced blood collection tubes. The company's flagship product, RAPClot, utilizes recombinant ecarin and a protective formulation to rapidly produce high-quality serum from blood samples. This technology addresses a critical need in the industry for efficient serum production, especially for patients on anticoagulants like warfarin. Q-Sera's target clients include clinical laboratories, hospitals, and research institutions that require reliable and quick serum analysis for biochemical testing. The company generates revenue through the sale of its RAPClot serum tubes, leveraging a scalable and cost-effective manufacturing process. With a focus on international markets, Q-Sera aims to enhance laboratory efficiency and improve patient outcomes through its innovative solutions.
Keywords: blood collection tubes, serum production, RAPClot, recombinant ecarin, clinical laboratories, anticoagulants, biochemical analysis, medical technology, laboratory efficiency, patient outcomes.